Abstract
Desmopressin (DDAVP) was first used to treat patients with inherited coagulation disorders by Mannucci et al (1977).Subsequently, mechanisms of drug action, different formulations and dosage schedules have been studied (Nilsson and Lethagen 1991). Responses to DDAVP have suggested differences in types of von Willebrand’s disease (vWD) (Menon et al 1978), and this has been followed by greater understanding of vWD pathophysiology (Ruggeri and Zimmerman 1987). Administration of DDAVP reduces blood product consumption and the desire to decrease exposure where possible has led to attempts to expand the indications for its use. Its role in the treatment of disorders of haemostasis is in some instances well established, but in other situations its precise role is not defined (Mannucci 1988).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bachmann, F., 1980 Diagnostic approach to mild bleeding disorders. Semin. in Hematol. 17: 292.
Berry, E. W., 1990. Use of DDAVP and cryoprecipitate in mild to moderate haemophilia a and von Willebrand’s disease, in “Recent Advances in Hemophilia Care,” C. K., Kasper, ed. Alan R. Liss, NewYork. 324: 269.
Berry, P, R, Coster, A. B., Berry, E. W., 1977. Local use of epsilon aminocaproic acid in dental therapy. Thromb. Haemost 38: 373.
Dal Bo Zanon, R, Calzavara, M., Vicari., T., Miotti, A. Girolami, A., 1986, Dental extraction in congenital haemorrhagic patients, Folta Haematol. (Leipz) 113(6): 799.
Davies, J. A, and Tuddenham, E. G. D., 1987. Haemostasis and Thrombosis, in “Oxford Textbook of Medicine” Weatherall, D. J., Ledingham, J, G, G., Warrell, D. A, eds. Oxford University Press, Oxford. 19: 215.
de La Fuente, B., Kasper, C. K., Rickles, F. R, Hoyer, L. W., 1985. Response of patients with mild and moderate haemophilia A and von Willebrand disease to treatment with desmopressin. Ann. Intern. Med. 103: 6.
Ghirardini, A., Chistolini, A, Tirindelli, M. C., Di Paolantonio, T., Iacopino, G., Mariani, P., Chirletti, P., Agrestini, F., Mariani, G., 1988. Clinical evaluation of subcutaneously administered DDAVP. Thromb. Res 49: 363.
Kesteven, P. J., Holland, L. J., Lawrie, A. S., Savidge, G. F., 1984. Inhibitor to factor VIII in mild haemophilia. Thromb. Haemost., 52: 50.
Kobrinsky, N. L., Israels E. D., Gerrard J. M., Cheang, M. S., Watson, C. M., Bishop, P, J., 1984. Shortening of the bleeding time by 1-deamino-8-Darginine vasopressin in various bleeding disorders. Lancet 1: 1145–1148.
Lowe, G., Pettigrew, A, Middleton, S., Forbes, C. D., Prentice, C., R, M., 1977. DDAVP in haemophilia. Lancet 11: 614.
Mannucci, P, M., 1988. Desmopressin: a non transfusional form of treatment for congenital and acquired bleeding disorders. Blood 72; 5: 1449.
Mannucci, P. M., and Lusher, J. M., 1989 Desmopressin and thrombosis. Lancet 2: 676.
Mariani, G., Ciavarella, N., Mazzucconi, M. G., Antonceachi, S., Solinas, S., Ranierl, P. et al, 1984. Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in hemophilia and von Willebrand’s disease. A study of 43 patients. Clin.Lab Haematol 6: 229–238.
Menon, N. C., Beny, E. W., Ockelford, PA, 1978. Beneficial effect of DDAVP on bleeding time in von Willebrand’s disease (letter). Lancet 2: 743.
Nilsson, I. M., and Lethagen, S., 1991. C. M. Kessler, eds. Elsevier Science Publishers B. V. Pfueller, S. L., Howard, MA, White, J. G., Menon, C., Berry, E. W., 1987. Shortening of the bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in gray platelet syndrome. Thromb. Haemost. 58: 1060.
Ramstrom, G., Blomback, M., Egberg, N., Johnsson, H., Ljungberg, B., Schulman, S., 1989. Oral Surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985). Int. J Oral Maxillofac. Surg. 18: 130.
Rodeghiero, F., Castaman, G., Mannucci, P, M., 1991. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. Blood Reviews 5: 155–161.
Ruggeri, Z, M., and Zimmerman, T. S., 1987, von Willebrand factor and von Willebrand disease. Blood 70: 895.
Scharrer, I., 1991, The treatment of von willebrand’s disease, in ‘Hemophilia and von Willebrand’s disease in the 1990’s,’ J. M., Lusher and C. M., Kessler, eds. Elsevier Science Publishers B. V. Amsterdam.
Schulman, S., 1991. DDAVP — the multipotent drug inpatients with coagulopathies. Transfusion Med.Rev. 5: 132.
Sindet-Pedersen, S., Ingerlou, J, Ramstrom G., Blomback, M., 1988. Management of oral bleeding in haemophilia patients. Lancet (letter) 21: 566.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Berry, E.W., Berry, P.R. (1993). DDAVP — Clinical Use and Therapeutic Limitations in Patients with Congenital Bleeding Disorders: The Auckland Experience. In: Mariani, G., Mannucci, P.M., Cattaneo, M. (eds) Desmopressin in Bleeding Disorders. NATO ASI Series, vol 242. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2922-4_27
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2922-4_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6268-5
Online ISBN: 978-1-4615-2922-4
eBook Packages: Springer Book Archive